NASDAQ:CYCC Cyclacel Pharmaceuticals (CYCC) Stock Price, News & Analysis $1.73 +0.05 (+2.98%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.61▼$1.7450-Day Range$1.50▼$2.6452-Week Range$1.30▼$11.34Volume76,107 shsAverage Volume461,999 shsMarket Capitalization$2.53 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Cyclacel Pharmaceuticals alerts: Email Address Cyclacel Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside535.8% Upside$11.00 Price TargetShort InterestHealthy8.26% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.29Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.93) to ($4.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.49 out of 5 stars 3.3 Analyst's Opinion Consensus RatingCyclacel Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCyclacel Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Cyclacel Pharmaceuticals' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted8.26% of the float of Cyclacel Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCyclacel Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cyclacel Pharmaceuticals has recently decreased by 32.40%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCyclacel Pharmaceuticals does not currently pay a dividend.Dividend GrowthCyclacel Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CYCC. Previous Next 4.0 News and Social Media Coverage News SentimentCyclacel Pharmaceuticals has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cyclacel Pharmaceuticals this week, compared to 0 articles on an average week.Search Interest4 people have searched for CYCC on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows4 people have added Cyclacel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cyclacel Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.00% of the stock of Cyclacel Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 23.58% of the stock of Cyclacel Pharmaceuticals is held by institutions.Read more about Cyclacel Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cyclacel Pharmaceuticals are expected to grow in the coming year, from ($4.93) to ($4.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cyclacel Pharmaceuticals is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cyclacel Pharmaceuticals is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCyclacel Pharmaceuticals has a P/B Ratio of 3.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cyclacel Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressThis TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.But I can promise that you’ll see all the details for yourself here. About Cyclacel Pharmaceuticals Stock (NASDAQ:CYCC)Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.Read More CYCC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYCC Stock News HeadlinesJune 26, 2024 | globenewswire.comCyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical CompositionsJune 4, 2024 | globenewswire.comCyclacel's Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual MeetingJuly 26, 2024 | WealthPress (Ad)This TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.May 14, 2024 | investorplace.comCYCC Stock Earnings: Cyclacel Pharmaceuticals Beats EPS for Q1 2024May 8, 2024 | globenewswire.comCyclacel Pharmaceuticals to Release First Quarter 2024 Financial ResultsMay 2, 2024 | globenewswire.comCyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ RulesApril 30, 2024 | msn.comWhy Is Cyclacel Pharmaceuticals (CYCC) Stock Up 46% Today?April 30, 2024 | investorplace.comWhy Is Cyclacel Pharmaceuticals (CYCC) Stock Up 46% Today?July 26, 2024 | WealthPress (Ad)This TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.April 30, 2024 | globenewswire.comCyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq RulesApril 29, 2024 | marketwatch.comCyclacel Pharmaceuticals Shares Up 72% After Hours on Withdrawal of OfferingApril 26, 2024 | marketwatch.comCyclacel Pharmaceuticals Shares Hit All-Time Low on Planned Equity SaleApril 25, 2024 | finance.yahoo.comCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Is Expected To Breakeven In The Near FutureApril 1, 2024 | globenewswire.comCyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for CancerMarch 27, 2024 | money.usnews.comCyclacel Pharmaceuticals IncMarch 21, 2024 | seekingalpha.comCyclacel Pharmaceuticals, Inc. (CYCC) Q4 2023 Earnings Call TranscriptMarch 20, 2024 | finance.yahoo.comCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2023 Earnings Call TranscriptMarch 19, 2024 | msn.comCYCC Stock Earnings: Cyclacel Pharmaceuticals Misses EPS for Q4 2023See More Headlines Receive CYCC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CYCC CUSIPN/A CIK1130166 Webwww.cyclacel.com Phone(908) 517-7330Fax866-271-3466Employees2,018Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Potential Upside/Downside+535.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($22.4430) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,560,000.00 Net Margins-4,401.34% Pretax Margin-5,061.69% Return on Equity-1,009.04% Return on Assets-180.03% Debt Debt-to-Equity RatioN/A Current Ratio0.58 Quick Ratio0.58 Sales & Book Value Annual Sales$420,000.00 Price / Sales6.01 Cash FlowN/A Price / Cash FlowN/A Book Value$0.57 per share Price / Book3.04Miscellaneous Outstanding Shares1,460,000Free Float1,346,000Market Cap$2.53 million OptionableOptionable Beta0.59 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Spiro George Rombotis (Age 65)President, CEO & Executive Director Comp: $612.47kMr. Paul McBarron (Age 63)Executive VP of Finance, CFO, COO, Secretary & Executive Director Comp: $321.61kDr. Brian Schwartz M.D. (Age 62)Interim Chief Medical Officer & Director Comp: $53kMs. Gill Christie (Age 67)Director of Human Resources Grace KimInvestor Relations ExecutiveKey CompetitorsAgile TherapeuticsNASDAQ:AGRXAeterna ZentarisNASDAQ:AEZSPurple BiotechNASDAQ:PPBTMolecular TemplatesNASDAQ:MTEMCyclerion TherapeuticsNASDAQ:CYCNView All CompetitorsInsiders & InstitutionsAcadian Asset Management LLCSold 9,938 shares on 5/10/2024Ownership: 1.084%Spiro George RombotisBought 6,070 shares on 12/21/2023Total: $20,091.70 ($3.31/share)Paul McbarronBought 1,886 shares on 12/21/2023Total: $6,242.66 ($3.31/share)View All Insider TransactionsView All Institutional Transactions CYCC Stock Analysis - Frequently Asked Questions How have CYCC shares performed this year? Cyclacel Pharmaceuticals' stock was trading at $2.67 at the beginning of the year. Since then, CYCC shares have decreased by 35.2% and is now trading at $1.73. View the best growth stocks for 2024 here. How were Cyclacel Pharmaceuticals' earnings last quarter? Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) released its quarterly earnings results on Tuesday, May, 14th. The biotechnology company reported ($2.27) EPS for the quarter, beating analysts' consensus estimates of ($4.93) by $2.66. The biotechnology company had revenue of $0.03 million for the quarter. Cyclacel Pharmaceuticals had a negative trailing twelve-month return on equity of 1,009.04% and a negative net margin of 4,401.34%. When did Cyclacel Pharmaceuticals' stock split? Cyclacel Pharmaceuticals shares reverse split on Monday, December 18th 2023. The 1-15 reverse split was announced on Monday, December 18th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, December 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What is Spiro Rombotis' approval rating as Cyclacel Pharmaceuticals' CEO? 1 employees have rated Cyclacel Pharmaceuticals Chief Executive Officer Spiro Rombotis on Glassdoor.com. Spiro Rombotis has an approval rating of 100% among the company's employees. This puts Spiro Rombotis in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. How do I buy shares of Cyclacel Pharmaceuticals? Shares of CYCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Cyclacel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cyclacel Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Vaxart (VXRT), NVIDIA (NVDA), Novavax (NVAX) and Gilead Sciences (GILD). This page (NASDAQ:CYCC) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclacel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYCC Stock Alerts